FI955101A - Immunogeenisia LHRH-peptidirakenteita ja synteettisiä immunosysteemin yleisstimulaattoreita rokotteita varten - Google Patents

Immunogeenisia LHRH-peptidirakenteita ja synteettisiä immunosysteemin yleisstimulaattoreita rokotteita varten Download PDF

Info

Publication number: FI955101A
Authority: FI; Finland
Prior art keywords: peptides; lhrh; peptide; helper; cell epitope
Prior art date: 1993-04-27

Application number

FI955101A

Other languages

English (en)

Swedish (sv)

Other versions

FI955101A0 (fi

Inventor

Anna E Ladd

Chang Yi Wang

Timothy Zamb

Original Assignee

United Biomedical Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-27

Filing date

1995-10-26

Publication date

1995-12-21

1995-10-26 Application filed by United Biomedical Inc filed Critical United Biomedical Inc

1995-10-26 Publication of FI955101A0 publication Critical patent/FI955101A0/fi

1995-12-21 Publication of FI955101A publication Critical patent/FI955101A/fi

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 14
230000002163 immunogen Effects 0.000 title abstract 3
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 title 1
102100024028 Progonadoliberin-1 Human genes 0.000 title 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 title 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 10
108700012941 GNRH1 Proteins 0.000 abstract 6
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 6
230000001419 dependent effect Effects 0.000 abstract 3
210000002443 helper t lymphocyte Anatomy 0.000 abstract 3
201000009030 Carcinoma Diseases 0.000 abstract 2
101710198693 Invasin Proteins 0.000 abstract 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
239000003098 androgen Substances 0.000 abstract 2
206010003694 Atrophy Diseases 0.000 abstract 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
241000606161 Chlamydia Species 0.000 abstract 1
201000009273 Endometriosis Diseases 0.000 abstract 1
102400000921 Gastrin Human genes 0.000 abstract 1
102000004862 Gastrin releasing peptide Human genes 0.000 abstract 1
108090001053 Gastrin releasing peptide Proteins 0.000 abstract 1
108010052343 Gastrins Proteins 0.000 abstract 1
102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 1
108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 1
101710105759 Major outer membrane porin Proteins 0.000 abstract 1
101710164702 Major outer membrane protein Proteins 0.000 abstract 1
241000224017 Plasmodium berghei Species 0.000 abstract 1
206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
241000700159 Rattus Species 0.000 abstract 1
230000037444 atrophy Effects 0.000 abstract 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000036039 immunity Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
208000000509 infertility Diseases 0.000 abstract 1
230000036512 infertility Effects 0.000 abstract 1
231100000535 infertility Toxicity 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
208000025661 ovarian cyst Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000001681 protective effect Effects 0.000 abstract 1
230000000306 recurrent effect Effects 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1
230000002381 testicular Effects 0.000 abstract 1
229960003604 testosterone Drugs 0.000 abstract 1
201000007331 uterine benign neoplasm Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57572—Gastrin releasing peptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Toxicology (AREA)
Zoology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Obesity (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Gynecology & Obstetrics (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)

FI955101A 1993-04-27 1995-10-26 Immunogeenisia LHRH-peptidirakenteita ja synteettisiä immunosysteemin yleisstimulaattoreita rokotteita varten FI955101A (fi)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5716693A	1993-04-27	1993-04-27
US22927594A	1994-04-14	1994-04-14
PCT/US1994/004832 WO1994025060A1 (en)	1993-04-27	1994-04-28	Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines

Publications (2)

Publication Number	Publication Date
FI955101A0 FI955101A0 (fi)	1995-10-26
FI955101A true FI955101A (fi)	1995-12-21

Family

ID=26736147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI955101A FI955101A (fi)	1993-04-27	1995-10-26	Immunogeenisia LHRH-peptidirakenteita ja synteettisiä immunosysteemin yleisstimulaattoreita rokotteita varten

Country Status (11)

Country	Link
EP (1)	EP0708656B1 (fi)
JP (2)	JP3795914B2 (fi)
AT (1)	ATE221387T1 (fi)
AU (1)	AU687805B2 (fi)
CA (1)	CA2161445C (fi)
DE (1)	DE69431114T2 (fi)
DK (1)	DK0708656T3 (fi)
ES (1)	ES2180576T3 (fi)
FI (1)	FI955101A (fi)
NO (1)	NO316121B1 (fi)
WO (1)	WO1994025060A1 (fi)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6607727B1 (en)	1991-08-26	2003-08-19	The Scripps Research Institute	Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6235288B1 (en)	1992-08-26	2001-05-22	The Scripps Research Institute	Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
CN1118573A (zh) *	1993-02-26	1996-03-13	斯克瑞普斯研究所	诱导细胞毒t淋巴细胞应答乙型肝炎病毒的肽类
US5688506A (en) *	1994-01-27	1997-11-18	Aphton Corp.	Immunogens against gonadotropin releasing hormone
JPH09510975A (ja) *	1994-03-28	1997-11-04	ユナイテッド・バイオメディカル・インコーポレイテッド	アレルギー治療用合成ペプチドベース免疫原
US6410022B1 (en)	1995-05-01	2002-06-25	Avant Immunotherapeutics, Inc.	Modulation of cholesteryl ester transfer protein (CETP) activity
EP0831881B1 (en)	1995-06-06	2003-03-12	Avant Immunotherapeutics, Inc.	Cetp for increasing hdl cholesterol level
US5843462A (en)	1995-11-30	1998-12-01	Regents Of The University Of Minnesota	Diphtheria toxin epitopes
HUP9901109A3 (en)	1996-03-01	1999-11-29	Novartis Ag	Peptide immunogens for vaccination against and treatment of allergy
JP2000510332A (ja)	1996-04-19	2000-08-15	ヘンリーエム．ジャクソンファンデーションフォーザアドバンスメントオブミリタリーメディシン	インチミンを単独で、または１以上の他の抗原との融合タンパク質として発現する宿主生物の投与による、免疫応答を刺激する方法
US6846808B1 (en)	1996-05-01	2005-01-25	Avant Immunotherapeutics, Inc.	Plasmid-based vaccine for treating atherosclerosis
US6284533B1 (en)	1996-05-01	2001-09-04	Avant Immunotherapeutics, Inc.	Plasmid-based vaccine for treating atherosclerosis
US6309646B1 (en)	1996-05-09	2001-10-30	The Henry M. Jackson Foundation For The Advancement Of Military Medicine	Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
DE69739233D1 (de) *	1996-06-25	2009-03-12	Pepscan Systems Bv	Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
DK0996717T3 (da) *	1997-08-05	2006-04-10	Vlaams Interuniv Inst Biotech	Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination
CA2315537A1 (en)	1997-12-16	1999-06-24	Regents Of The University Of Minnesota	Methods to treat undesirable immune responses
US6107021A (en) *	1998-06-20	2000-08-22	United Biomedical, Inc.	Synthetic peptide vaccines for foot-and-mouth disease
US6090388A (en) *	1998-06-20	2000-07-18	United Biomedical Inc.	Peptide composition for prevention and treatment of HIV infection and immune disorders
TWI227241B (en)	1998-06-20	2005-02-01	United Biomedical Inc	IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6025468A (en) *	1998-06-20	2000-02-15	United Biomedical, Inc.	Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
WO2000032626A1 (en) *	1998-11-25	2000-06-08	Regents Of The University Of Minnesota	Methods of using epitope peptides of human pathogens
UA81216C2 (en) *	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US6783761B2 (en)	2000-05-05	2004-08-31	Aphton Corporation	Chimeric peptide immunogens
US6780969B2 (en) *	2000-12-22	2004-08-24	United Biomedical, Inc.	Synthetic peptide composition as immunogens for prevention of urinary tract infection
US6906169B2 (en) *	2001-05-25	2005-06-14	United Biomedical, Inc.	Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) *	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
PL209696B1 (pl) *	2002-04-19	2011-10-31	Univ Toronto	Peptyd, kompozycja peptydowa, kompozycja immunogenna, zastosowania kompozycji immunogennej oraz sposób określania czy związek stanowi inhbitor odkładania się i tworzenia włókienek amyloidu
US8709998B2 (en)	2003-04-22	2014-04-29	Ipsen Pharma S.A.S.	Peptide vectors
ZA200702329B (en) *	2004-09-10	2008-06-25	Queensland Inst Med Res	Truncated LHRH formulations
AU2006247188A1 (en)	2005-05-18	2006-11-23	Children's Hospital & Research Center At Oakland	Methods and compositions for immunizing against chlamydia infection
AU2006253914A1 (en) *	2005-06-01	2006-12-07	Pfizer Products Inc.	Vaccine compositions and methods for the treatment of urinary incontinence
JP2010539037A (ja) *	2007-09-11	2010-12-16	モンドバイオテックラボラトリーズアクチエンゲゼルシャフト	治療剤としてのペプチドの使用
JP4535174B2 (ja)	2008-07-11	2010-09-01	トヨタ自動車株式会社	車両の制御装置および制御方法
HUE051277T2 (hu)	2012-11-16	2021-03-01	United Biomedical Inc	Szintetikus peptiden alapuló sürgõsségi vakcina ragadós száj- és körömfájás (FMD) ellen
US20170216418A1 (en) *	2014-07-25	2017-08-03	United Biomedical, Inc.	Immunogenic lhrh composition and use thereof in pigs
KR102317805B1 (ko) *	2017-03-30	2021-10-27	이씨에스-프로가스트린 에스에이	전립선암을 검출하기 위한 조성물 및 방법
TW202144387A (zh) *	2020-02-11	2021-12-01	美商聯合生物醫學公司	針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4613586A (en) *	1984-04-19	1986-09-23	Board Of Trustees Of The Leland Stanford Junior University	Gastrin releasing peptide-like peptides
US4608251A (en) *	1984-11-09	1986-08-26	Pitman-Moore, Inc.	LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
EP0301850A3 (en) *	1987-07-31	1990-10-31	Syntex (U.S.A.) Inc.	Lhrh antagonist analogs and 19-nor-progestational steroids for therapy
GB8812214D0 (en) *	1988-05-24	1988-06-29	Hoffmann La Roche	Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5171835A (en) *	1988-10-21	1992-12-15	The Administrators Of The Tulane Educational Fund	LHRH antagonists
GB8913737D0 (en) *	1989-06-15	1989-08-02	Univ Birmingham	A novel anti-allergy treatment
GB8924438D0 (en) *	1989-10-31	1989-12-20	Hoffmann La Roche	Vaccine composition
IT1237764B (it) *	1989-11-10	1993-06-17	Eniricerche Spa	Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
CH683101A5 (de) *	1990-09-18	1994-01-14	Biotech Australia Pty Ltd	T-Zellen-Epitope.
EP0584212A4 (en) *	1991-05-13	1994-11-30	Univ California	LIPOSOMAL POLYSACCHARID VACCINE.
IL102964A0 (en) *	1991-08-26	1993-01-31	Cytel Corp	Hla-restricted hepatitis b virus ctl epitopes

1994
- 1994-04-28 JP JP52461494A patent/JP3795914B2/ja not_active Expired - Lifetime
- 1994-04-28 AU AU66702/94A patent/AU687805B2/en not_active Expired
- 1994-04-28 AT AT94915447T patent/ATE221387T1/de active
- 1994-04-28 EP EP94915447A patent/EP0708656B1/en not_active Expired - Lifetime
- 1994-04-28 DE DE69431114T patent/DE69431114T2/de not_active Expired - Lifetime
- 1994-04-28 ES ES94915447T patent/ES2180576T3/es not_active Expired - Lifetime
- 1994-04-28 DK DK94915447T patent/DK0708656T3/da active
- 1994-04-28 WO PCT/US1994/004832 patent/WO1994025060A1/en active IP Right Grant
- 1994-04-28 CA CA002161445A patent/CA2161445C/en not_active Expired - Lifetime
1995
- 1995-10-26 FI FI955101A patent/FI955101A/fi not_active Application Discontinuation
- 1995-10-26 NO NO19954279A patent/NO316121B1/no not_active IP Right Cessation
2004
- 2004-10-06 JP JP2004293637A patent/JP2005060406A/ja active Pending

Also Published As

Publication number	Publication date
FI955101A0 (fi)	1995-10-26
AU687805B2 (en)	1998-03-05
JPH09503742A (ja)	1997-04-15
EP0708656A1 (en)	1996-05-01
ATE221387T1 (de)	2002-08-15
EP0708656B1 (en)	2002-07-31
DE69431114T2 (de)	2003-03-13
DE69431114D1 (de)	2002-09-05
DK0708656T3 (da)	2002-12-02
EP0708656A4 (en)	1999-06-23
NO954279L (no)	1995-12-27
WO1994025060A1 (en)	1994-11-10
ES2180576T3 (es)	2003-02-16
CA2161445A1 (en)	1994-11-10
NO316121B1 (no)	2003-12-15
NO954279D0 (no)	1995-10-26
JP3795914B2 (ja)	2006-07-12
AU6670294A (en)	1994-11-21
JP2005060406A (ja)	2005-03-10
CA2161445C (en)	2009-06-30

Legal Events

Date	Code	Title	Description
2004-10-09	FD	Application lapsed	Free format text: KVAERNER PULPING TECHNOLOGIES AB

Publication	Publication Date	Title
FI955101A (fi)	1995-12-21	Immunogeenisia LHRH-peptidirakenteita ja synteettisiä immunosysteemin yleisstimulaattoreita rokotteita varten
DE69511379D1 (en)	1999-09-16	Immunogens gegen gonadotropin releasing hormone
IL146482A0 (en)	2002-07-25	Tek antagonists
WO1997035021A3 (en)	1997-10-30	Prostate specific antigen oligo-epitope peptide
CY2457B1 (en)	2005-06-03	Peptide immunogens for vaccination against and treatment of allergy.
AU585605B2 (en)	1989-06-22	GnRH antagonists IX
Giri et al.	1990	Histopathological changes in reproductive organs of male Wistar rats following active immunization against LHRH
EP1820514A3 (en)	2007-10-17	Therapeutic compositions that produce an immune response by altering the antigen
WO2002022659A3 (en)	2003-01-23	DISCRIMINATION BETWEEN GnRH-I AND GnRH-II
Limonta et al.	1998	Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II, Jungwirth et al., Eur J Cancer 1997, 33 (7), 1141-1148
Ablin	1977	Hormonal epidemiology of prostatic cancer
Baldwin et al.	1982	Cellular interactions modulating host resistance to tumours
Weiss et al.	1975	Proceedings: recent studies with the methanol extraction residue fraction of tubercle bacilli (MER): efficacy of distal administration against solid tumors of experimental animals, and stimulation of cellular immunologic responsiveness in cancer patients
Gallagher	1988	Lightning on the Links
Swerdloff et al.	1996	GnRH analogues and male contraception
MX2022003100A (es)	2022-04-06	Un inmunoterapeutico para el tratamiento del cancer de prostata.
AU1936001A (en)	2001-06-12	A major neutralization site of hepatitis E virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis E virus
DE1726895U (de)	1956-07-26	Kurzwellen-therapieapparat.